EA005411B1 - Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей - Google Patents

Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей Download PDF

Info

Publication number
EA005411B1
EA005411B1 EA200000310A EA200000310A EA005411B1 EA 005411 B1 EA005411 B1 EA 005411B1 EA 200000310 A EA200000310 A EA 200000310A EA 200000310 A EA200000310 A EA 200000310A EA 005411 B1 EA005411 B1 EA 005411B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
sequences
dna
specified
receptor
Prior art date
Application number
EA200000310A
Other languages
English (en)
Russian (ru)
Other versions
EA200000310A1 (ru
Inventor
Юрг Чопп
Original Assignee
Апотек Р Энд Д Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апотек Р Энд Д Са filed Critical Апотек Р Энд Д Са
Publication of EA200000310A1 publication Critical patent/EA200000310A1/ru
Publication of EA005411B1 publication Critical patent/EA005411B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA200000310A 1997-09-12 1998-09-11 Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей EA005411B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US7938498P 1998-03-26 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (2)

Publication Number Publication Date
EA200000310A1 EA200000310A1 (ru) 2000-10-30
EA005411B1 true EA005411B1 (ru) 2005-02-24

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000310A EA005411B1 (ru) 1997-09-12 1998-09-11 Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей

Country Status (20)

Country Link
US (3) US20030138884A1 (cg-RX-API-DMAC7.html)
EP (1) EP1027431A2 (cg-RX-API-DMAC7.html)
JP (1) JP2001515712A (cg-RX-API-DMAC7.html)
KR (1) KR100618492B1 (cg-RX-API-DMAC7.html)
CN (1) CN1195849C (cg-RX-API-DMAC7.html)
AU (1) AU759717B2 (cg-RX-API-DMAC7.html)
BR (1) BR9812634A (cg-RX-API-DMAC7.html)
CA (1) CA2303615A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ294615B6 (cg-RX-API-DMAC7.html)
EA (1) EA005411B1 (cg-RX-API-DMAC7.html)
EE (1) EE200000147A (cg-RX-API-DMAC7.html)
HU (1) HUP0004611A3 (cg-RX-API-DMAC7.html)
IL (1) IL134537A0 (cg-RX-API-DMAC7.html)
IS (1) IS5378A (cg-RX-API-DMAC7.html)
NO (1) NO20001242L (cg-RX-API-DMAC7.html)
NZ (1) NZ503850A (cg-RX-API-DMAC7.html)
PL (1) PL339463A1 (cg-RX-API-DMAC7.html)
SK (1) SK3542000A3 (cg-RX-API-DMAC7.html)
TR (1) TR200000669T2 (cg-RX-API-DMAC7.html)
WO (1) WO1999012965A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2671101C1 (ru) * 2013-11-19 2018-10-29 Регенерон Фармасьютикалс, Инк. Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6440694B1 (en) * 1997-09-30 2002-08-27 Pharmacia & Upjohn Company TNF-related death ligand
WO1999026976A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
CZ299819B6 (cs) 1999-01-25 2008-12-03 Biogen Idec Ma Inc. Farmaceutické kompozice obsahující protilátky specifické pro rozpustný BAFF
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
HK1043608B (en) * 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
EP1259544B1 (en) 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologous polypeptide of the tnf family
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
AU2001263114A1 (en) * 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1294949A4 (en) * 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
US7189820B2 (en) 2001-05-24 2007-03-13 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (APRIL)
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
EP1608730B1 (en) 2003-03-28 2013-11-06 Biogen Idec MA Inc. Truncated baff receptors
WO2005075511A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
AU2005318086B2 (en) 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
KR20080056714A (ko) 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 TACI―Ig 융합 분자를 사용하여 B―세포 악성종양을치료하는 방법
CA2623530C (en) 2005-09-26 2015-02-03 Apotech Corporation Antibodies against april as biomarkers for early prognosis of lymphoma patients
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007134326A2 (en) 2006-05-15 2007-11-22 Ares Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
WO2010100056A2 (en) 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
EP2542679A1 (en) * 2010-03-05 2013-01-09 Academisch Medisch Centrum bij de Universiteit van Amsterdam B-cell stimulating fusion proteins of an antigen with baff or april
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
HRP20231121T1 (hr) * 2013-09-23 2023-12-22 Regeneron Pharmaceuticals, Inc. Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170145086A1 (en) 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
JP2023548866A (ja) 2020-10-29 2023-11-21 インダストリアル ポリマーズ アンド ケミカルズ, インコーポレイテッド 病原体監視及び不活性化のエアフィルター
CA3228678A1 (en) 2021-08-11 2023-02-16 Amato J. Giaccia Methods of reducing production of iga, igm and/or igg using sbcma variants and fc fusion proteins thereof
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記55有限公司 Cd19/cd38多特異性抗體
CN118909083A (zh) * 2024-07-30 2024-11-08 江苏省农业科学院 一种猪b细胞增殖诱导配体蛋白及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADAMS M.D. ET AL.: "EST71242 T-cell lymphoma Homo sapiens cDNA 5' end", EMBL DATABASE, 18 April 1997, XP002099002, HEIDELBERG, DE, Accession Number: AA361896 *
HAHNE M. ET AL.: "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth", JOURNAL OF EXPERIMENTAL MEDICINE, vol 188. no. 6, 21 September 1998, pages 1185-1190, XP002099001, US, see the whole document *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2671101C1 (ru) * 2013-11-19 2018-10-29 Регенерон Фармасьютикалс, Инк. Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда

Also Published As

Publication number Publication date
IS5378A (is) 2000-02-18
JP2001515712A (ja) 2001-09-25
EA200000310A1 (ru) 2000-10-30
NO20001242L (no) 2000-05-11
EE200000147A (et) 2001-02-15
NZ503850A (en) 2002-12-20
CN1195849C (zh) 2005-04-06
CZ294615B6 (cs) 2005-02-16
KR100618492B1 (ko) 2006-08-31
SK3542000A3 (en) 2000-08-14
TR200000669T2 (tr) 2000-08-21
CN1270632A (zh) 2000-10-18
US20030138884A1 (en) 2003-07-24
AU9316298A (en) 1999-03-29
EP1027431A2 (en) 2000-08-16
WO1999012965A3 (en) 1999-06-03
BR9812634A (pt) 2000-08-22
PL339463A1 (en) 2000-12-18
CA2303615A1 (en) 1999-03-18
AU759717B2 (en) 2003-04-17
WO1999012965A2 (en) 1999-03-18
IL134537A0 (en) 2001-04-30
HUP0004611A3 (en) 2002-04-29
CZ2000869A3 (cs) 2000-09-13
NO20001242D0 (no) 2000-03-09
US20050112596A1 (en) 2005-05-26
KR20010023893A (ko) 2001-03-26
US20060084148A1 (en) 2006-04-20
HUP0004611A2 (hu) 2001-04-28

Similar Documents

Publication Publication Date Title
KR100618492B1 (ko) 성장 효과가 있는 단백질 april
JP4411330B2 (ja) 腫瘍壊死因子関連リガンド
KR100373813B1 (ko) 이관능성단백질,그의제조및용도
JP2001515711A (ja) Kay−新規の免疫系タンパク質
EA005601B1 (ru) Способ лечения злокачественных опухолей у млекопитающего, характеризующихся аномально высокой экспрессией лиганда, индуцирующего пролиферацию клеток (april)
AU2001253920A1 (en) Use of taci as an anti-tumor agent
WO2001081417A2 (en) Use of taci as an anti-tumor agent
JP2011172588A (ja) Dp75をコードするdnaおよびその使用のためのプロセス
KR20010015869A (ko) 레스틴 및 그의 사용 방법
JP2000508894A (ja) 細胞外/上皮増殖因子hcaba58x
JP2001501909A (ja) 癌ワクチンとして有用な細胞性イムノゲン
JP2000508531A (ja) 細胞外/上皮増殖因子様タンパク質
US20040249145A1 (en) Cell adhesion-mediating proteins and polynucleotides encoding them
MXPA00002407A (en) April- a novel protein with growth effects
AU2003213481A1 (en) APRIL - A Novel Protein With Growth Effects
JP2003511388A (ja) 繊維芽細胞増殖因子−5(fgf−5)は腫瘍関連t細胞抗原である
JP2000506371A (ja) 成長因子htter36
CZ2000867A3 (cs) Sekvence DNA kódující ligand Kay, způsob přípravy ligandu Kay a farmaceutický přípravek obsahující tento ligand
JP2003245089A (ja) 免疫細胞サイトカイン
JP2003000247A (ja) トランスフォーミング増殖因子αHII
JPH11507208A (ja) アポトーシス遺伝子1のヒトインヒビター